Abstract
The aim of this study was to investigate the reactivation of the hepatitis B virus (HBV) following transarterial chemoembolization (TACE) in primary hepatocellular carcinoma (HCC) patients with HBV-DNA negative and to evaluate the effects of TACE combined with antiviral therapy. This prospective study involved 98 patients with HBV-related and HBV-DNA negative HCC (HBV DNA < 10 copies/mL) underwent TACE procedures with serial HBV DNA tests. Patients were divided into the antiviral treatment group and the no-antiviral group. The antiviral group received entecavir antiviral therapy, and the other group received no antiviral therapy. Two groups of patients were compared in rate of HBV reactivation and liver function before and after only 1 session of TACE in average 1-month follow-up after operation. P < .05 indicated differences with a statistical significance. HBV reactivation occurred in 11 patients in the nonantiviral group (11/47, 23.4%) but only 3 patients in the antiviral group (3/51, 5.9%, P < .05). On multivariate analysis, HBeAg-positive status, number of tumors more than 3, and absence of antiviral therapy were the independent risk predictor of HBV reactivation. Liver function indicators did not differ significantly betw...Continue Reading
References
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vincent Wai-Sun WongTony Shu-Kam Mok
May 28, 2011·European Journal of Gastroenterology & Hepatology·Zhuanbo LuoBing Ruan
Oct 26, 2011·Antiviral Therapy·Jeong Won JangKyu Won Chung
Mar 23, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver
May 23, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Akira IkomaTetsuo Sonomura
Aug 8, 2012·Annals of Surgery·Gang HuangMeng-chao Wu
Apr 20, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J-Q DanW Y Lau
Aug 5, 2014·ANZ Journal of Surgery·Jian-Jun LengJia-Hong Dong
Nov 8, 2014·Journal of Viral Hepatitis·W SohnB C Yoo
Dec 3, 2014·Gastroenterology·Robert P PerrilloYngve T Falck-Ytter
Jun 1, 2012·Hepatology International·Yun-Fan LiawMasao Omata
Sep 18, 2015·Therapeutics and Clinical Risk Management·Wenbo ShaoJinlong Song
Oct 18, 2015·Antiviral Research·Ejuan ZhangMichael Roggendorf
Jan 8, 2016·Hepatology International·Man-Fung Yuen
Apr 6, 2016·Clinical and Molecular Hepatology·Jung Min LeeChang Hyeong Lee
Apr 24, 2016·Digestive Diseases and Sciences·Xiao-Jun LinSheng-Ping Li
Citations
Mar 16, 2019·Digestive Diseases and Sciences·Jordan J Feld, Lisette A P Krassenburg
May 19, 2020·Antiviral Chemistry & Chemotherapy·Mohamed A Abd El AzizAntonio Facciorusso
Jul 19, 2019·IET Systems Biology·Yi Ding, Wen-June Wang
Feb 23, 2021·Frontiers in Oncology·Shousheng LiuMing Zhao
Mar 25, 2021·Journal of Viral Hepatitis·Myung Pyo KimSae Hwan Lee
May 28, 2021·Cancer Management and Research·Xinhua ZouJiaping Li
Jul 29, 2021·World Journal of Gastrointestinal Pharmacology and Therapeutics·Niraj James ShahKumar Pallav
Jun 9, 2021·Bioscience Reports·Xu ChaoChao Jiang
Oct 2, 2021·Chinese Medical Journal·Zhan-Qi Wei, Yue-Wei Zhang